$25.50
0.34 (+1.35%)
Bristol-Myers Squibb Co. (BMY)
CAPS Rating:
The Company, through its divisions and subsidiaries, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and other health care related products.
RSS Headlines
Fool UK
Recs
As safe as they come in this industry. While it has potential challenges with patent expirations especially with Plavix, it has an underrated pipeline, strong balance sheet and a solid, dependable 5% dividend (hasn't missed a dividend payment in over 50 years!). In this uncertain market, this is stock that you can buy and sleep easy on.